Kirk A. Frey
#141,918
Most Influential Person Now
Kirk A. Frey's AcademicInfluence.com Rankings
Kirk A. Freyphilosophy Degrees
Philosophy
#7439
World Rank
#10655
Historical Rank
Logic
#4490
World Rank
#5794
Historical Rank

Kirk A. Freybiology Degrees
Biology
#10104
World Rank
#13400
Historical Rank
Neuroscience
#1533
World Rank
#1584
Historical Rank

Download Badge
Philosophy Biology
Kirk A. Frey's Degrees
- PhD Neuroscience Stanford University
- Doctorate Medicine Stanford University
Why Is Kirk A. Frey Influential?
(Suggest an Edit or Addition)Kirk A. Frey's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease (1997) (1671)
- A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. (1995) (1009)
- Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations (1997) (530)
- Positron emission tomographic analysis of cerebral structures activated specifically by repetitive noxious heat stimuli. (1994) (506)
- Alzheimer's disease versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation (2001) (496)
- Anatomic standardization: linear scaling and nonlinear warping of functional brain images. (1994) (423)
- In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease (1996) (369)
- Hippocampal Inactivation Disrupts the Acquisition and Contextual Encoding of Fear Extinction (2005) (368)
- History of falls in Parkinson disease is associated with reduced cholinergic activity (2009) (354)
- Compartmental Analysis of [11C]Flumazenil Kinetics for the Estimation of Ligand Transport Rate and Receptor Distribution Using Positron Emission Tomography (1991) (351)
- In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease (1999) (336)
- Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging (1996) (308)
- Decreased striatal dopaminergic innervation in REM sleep behavior disorder (2000) (284)
- Automated detection of the intercommissural line for stereotactic localization of functional brain images. (1993) (271)
- Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease (2010) (267)
- Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. (2015) (238)
- Positron Emission Tomography of Monoaminergic Vesicular Binding in Aging and Parkinson Disease (2006) (237)
- Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease (1996) (225)
- Preserved Pontine Glucose Metabolism in Alzheimer Disease: A Reference Region for Functional Brain Image (PET) Analysis (1995) (212)
- The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. (1995) (207)
- Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease (2012) (204)
- In vivo cerebral metabolism and central benzodiazepine‐receptor binding in temporal lobe epilepsy (1993) (194)
- Cerebral Glucose Metabolic Features of Parkinson Disease and Incident Dementia: Longitudinal Study (2011) (193)
- Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome (2006) (192)
- Brain PET in suspected dementia: patterns of altered FDG metabolism. (2014) (181)
- Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease (2003) (180)
- Changes in [3H]muscimol binding in substantia nigra, entopeduncular nucleus, globus pallidus, and thalamus after striatal lesions as demonstrated by quantitative receptor autoradiography (1983) (178)
- Mutual Information for Automated Unwarping of Rat Brain Autoradiographs (1997) (169)
- Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. (1997) (167)
- Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options (2009) (165)
- Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review (2015) (157)
- A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. (2007) (156)
- Heterogeneity of Cholinergic Denervation in Parkinson's Disease without Dementia (2012) (155)
- Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer: A Phase 2 Clinical Trial (2017) (153)
- Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers (2006) (151)
- Increased ventral striatal monoaminergic innervation in Tourette syndrome (2003) (149)
- Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. (1996) (145)
- Localization of muscarinic M3 receptor protein and M3 receptor binding in rat brain (1994) (143)
- Motor correlates of occipital glucose hypometabolism in Parkinson’s disease without dementia (1999) (139)
- Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? (1995) (139)
- Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease. (2013) (136)
- Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex (2000) (133)
- In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM. (1994) (130)
- PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer's disease. (1995) (128)
- Quantitative autoradiography of [3H]muscimol binding in rat brain. (1981) (122)
- Striatal dopaminergic abnormalities in human cocaine users. (1999) (120)
- Differentiation of Radioligand Delivery and Binding in the Brain: Validation of a Two-Compartment Model for [11C]Flumazenil (1991) (114)
- Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. (1997) (112)
- Spared Caudal Brainstem SERT Binding in Early Parkinson's Disease (2008) (112)
- Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects. (2015) (111)
- Parametric in vivo imaging of benzodiazepine receptor distribution in human brain (1991) (110)
- Protein synthesis in the amygdala, but not the auditory thalamus, is required for consolidation of Pavlovian fear conditioning in rats (2003) (109)
- 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. (2005) (108)
- Kinetic Modeling of N-[11C]Methylpiperidin-4-yl Propionate: Alternatives for Analysis of an Irreversible Positron Emission Tomography Tracer for Measurement of Acetylcholinesterase Activity in Human Brain (1999) (104)
- In Vivo Imaging of Human Cholinergic Nerve Terminals with (–)-5-18F-Fluoroethoxybenzovesamicol: Biodistribution, Dosimetry, and Tracer Kinetic Analyses (2014) (104)
- [3H]methoxytetrabenazine: A high specific activity ligand for estimating monoaminergic neuronal integrity (1995) (103)
- Kinetic Evaluation of [11C]Dihydrotetrabenazine by Dynamic PET: Measurement of Vesicular Monoamine Transporter (1996) (103)
- Temporal lobe central benzodiazepine binding in unilateral mesial temporal lobe epilepsy (1995) (100)
- Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease. (2011) (99)
- Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers (2006) (97)
- Gait speed in Parkinson disease correlates with cholinergic degeneration (2013) (96)
- In vivo Muscarinic Cholingeric Receptor Imaging in Human Brain with [11C]Scopolamine and Positron Emission Tomography (1992) (96)
- Extra‐nigral pathological conditions are common in Parkinson's disease with freezing of gait: An in vivo positron emission tomography study (2014) (95)
- Metabotropic Glutamate Agonist-Induced Rotation: A Pharmacological, FOS Immunohistochemical, and [14C]-2-Deoxyglucose Autoradiographic Study (1997) (95)
- Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: what is the impact on staging? (2013) (92)
- Cholinergic system changes of falls and freezing of gait in Parkinson's disease (2019) (92)
- Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia (2012) (92)
- Imaging the vesicular monoamine transporter. (2001) (91)
- Binding of α-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific (1995) (91)
- Stereotactic PET atlas of the human brain: aid for visual interpretation of functional brain images. (1994) (91)
- Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma. (2008) (90)
- Diabetes is associated with postural instability and gait difficulty in Parkinson disease. (2013) (90)
- High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: sex differences and cognitive correlates. (2000) (89)
- Equilibrium versus Compartmental Analysis for Assessment of the Vesicular Monoamine Transporter Using (+)-α-[11C]Dihydrotetrabenazine (DTBZ) and Positron Emission Tomography (1997) (87)
- Vesicular neurotransmitter transporters in Huntington's disease: Initial observations and comparison with traditional synaptic markers (2001) (86)
- [18F]fluoroethoxy‐benzovesamicol, a PET radiotracer for the vesicular acetylcholine transporter and cholinergic synapses (1998) (85)
- Decreased striatal monoaminergic terminals in Huntington disease (2000) (84)
- β‐amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia (2013) (80)
- Dopamine transporter antagonists block phorbol ester-induced dopamine release and dopamine transporter phosphorylation in striatal synaptosomes. (2000) (79)
- Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters. (1996) (78)
- Probable diffuse Lewy body disease presenting as REM sleep behavior disorder (1997) (77)
- Assessment of Extrastriatal Vesicular Monoamine Transporter Binding Site Density Using Stereoisomers of [11C]Dihydrotetrabenazine (1999) (77)
- Positron emission tomography measures of benzodiazepine binding in Alzheimer's disease. (1995) (77)
- Differentiating Alzheimer’s disease from dementia with Lewy bodies and Parkinson’s disease with (+)-[11C]dihydrotetrabenazine positron emission tomography (2008) (76)
- Positron emission tomography measures of benzodiazepine receptors in Huntington's disease (1993) (76)
- Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects (2001) (75)
- Insomnia and sleepiness in Parkinson disease: associations with symptoms and comorbidities. (2013) (74)
- Initial agonist treatment of Parkinson disease (2003) (73)
- Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. (2014) (73)
- Reduced γ-aminobutyric acidA-benzodiazepine binding sites in insular cortex of individuals with panic disorder (2007) (72)
- Assessment of muscarinic receptor concentrations in aging and Alzheimer disease with [11C]NMPB and PET (2001) (70)
- High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection. (2014) (70)
- [11C]Tropanyl Benzilate—Binding to Muscarinic Cholinergic Receptors: Methodology and Kinetic Modeling Alternatives (1994) (69)
- [15O]H2O positron emission tomography determination of cerebral blood flow during balloon test occlusion of the internal carotid artery. (1994) (69)
- Autoradiographic mapping of M3 muscarinic receptors in the rat brain. (1993) (69)
- Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease (2014) (69)
- In Vivo Imaging of Vesicular Monoamine Transporters in Human Brain Using [11C]Tetrabenazine and Positron Emission Tomography (1993) (68)
- Striatal presynaptic monoaminergic vesicles are not increased in Tourette’s syndrome (1999) (66)
- GABAA receptor abnormalities in Prader–Willi syndrome assessed with positron emission tomography and [11C]flumazenil (2004) (66)
- Reliability of Repeated Cognitive Assessment of Dementia Using a Brief Computerized Battery (2011) (65)
- Use of Flutemetamol F 18–Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment (2018) (61)
- Evaluation of [(11)C]N-Methyl Lansoprazole as a Radiopharmaceutical for PET Imaging of Tau Neurofibrillary Tangles. (2012) (60)
- Imaging of Cholinergic and Monoaminergic Neurochemical Changes in Neurodegenerative Disorders (2007) (59)
- Staging of differentiated thyroid carcinoma using diagnostic 131I SPECT/CT. (2010) (59)
- Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease (2017) (59)
- In vivo imaging of the brain vesicular monoamine transporter. (1995) (59)
- Stable beta-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice. (2002) (59)
- Early menopausal hormone use influences brain regions used for visual working memory (2010) (59)
- In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses (2006) (59)
- Neuroimaging of Tourette Syndrome (2006) (58)
- Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors. (2010) (55)
- Decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography (1996) (55)
- FDG PET imaging of childhood sarcomas (2009) (55)
- Lymphatic Mapping and Sentinel Lymph Node Biopsy for Patients With Local Recurrence After Breast-Conservation Therapy (2006) (55)
- Clinical markers for identifying cholinergic deficits in Parkinson's disease (2015) (54)
- Striatal and Cortical β‐Amyloidopathy and Cognition in Parkinson's Disease (2016) (53)
- Comparison of 18F Flurodeoxyglucose PET with Ga-67 scintigraphy and conventional imaging modalities in pediatric lymphoma (2007) (52)
- In vivo muscarinic cholinergic receptor imaging in human brain with [11C]scopolamine and positron emission tomography. (1992) (52)
- Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol. (1996) (51)
- In Vivo Measurement of the Vesicular Monoamine Transporter in Schizophrenia (2000) (51)
- Positron emission tomography imaging of (2R,3R)-5-[(18)F]fluoroethoxybenzovesamicol in rat and monkey brain: a radioligand for the vesicular acetylcholine transporter. (2009) (50)
- Dopaminergic abnormalities in select thalamic nuclei in schizophrenia: involvement of the intracellular signal integrating proteins calcyon and spinophilin. (2005) (48)
- Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. (2011) (47)
- Cholinergic vesicular transporters in progressive supranuclear palsy (2002) (47)
- Striatal [11C]dihydrotetrabenazine and [11C]methylphenidate binding in Tourette syndrome (2009) (47)
- Neurochemical imaging of Alzheimer's disease and other degenerative dementias. (1998) (45)
- Quantitative in vivo receptor binding III: Tracer kinetic modeling of muscarinic cholinergic receptor binding. (1985) (45)
- Synthesis, in vivo biodistribution and dosimetry of [11C]N-methylpiperidyl benzilate ([11C]NMPB), a muscarinic acetylcholine receptor antagonist. (1995) (45)
- Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains. (1996) (45)
- Changes in global function and regional ventilation and perfusion on SPECT during the course of radiotherapy in patients with non-small-cell lung cancer. (2012) (45)
- In Vivo Quantification of Cerebral Muscarinic Receptors in Normal Human Aging Using Positron Emission Tomography and [11C]Tropanyl Benzilate (1996) (45)
- SNM Practice Guideline for Brain Death Scintigraphy 2.0 (2012) (43)
- Quantification of Muscarinic Cholinergic Receptors with [11C]NMPB and Positron Emission Tomography: Method Development and Differentiation of Tracer Delivery from Receptor Binding (1998) (43)
- Basal ganglia glucose utilization after recent precentral ablation in the monkey (1985) (43)
- Neuroimaging in Dementia with Lewy Bodies: Metabolism, Neurochemistry, and Morphology (2002) (43)
- Quantitative in vivo receptor binding. II. Autoradiographic imaging of muscarinic cholinergic receptors (1985) (43)
- Reduced gamma-aminobutyric acid(A)-benzodiazepine binding sites in insular cortex of individuals with panic disorder. (2007) (42)
- Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma. (2009) (42)
- Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias (2002) (41)
- Barbiturate-enhanced detection of brain lesions by carbon-14-labeled 2-deoxyglucose autoradiography. (1983) (41)
- Receptor Binding Techniques (1997) (40)
- Semiquantification and Classification of Local Pulmonary Function by V/Q Single Photon Emission Computed Tomography in Patients with Non-small Cell Lung Cancer: Potential Indication for Radiotherapy Planning (2011) (38)
- Regional vesicular acetylcholine transporter distribution in human brain: A [18F]fluoroethoxybenzovesamicol positron emission tomography study (2018) (38)
- Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of l-DOPA and pramipexole (2003) (38)
- Quantitative autoradiography of muscarinic cholinergic receptor binding in the rat brain: distinction of receptor subtypes in antagonist competition assays. (1992) (37)
- The value of 99mTc-MAA SPECT/CT for lung shunt estimation in 90Y radioembolization: a phantom and patient study (2018) (36)
- Effect of hyperglycemia on brain and liver 18F-FDG standardized uptake value (FDG SUV) measured by quantitative positron emission tomography (PET) imaging. (2017) (35)
- Pattern of cardiac sympathetic denervation in idiopathic Parkinson disease studied with 11C hydroxyephedrine PET. (2012) (34)
- Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. (1995) (33)
- In vivo [11C]dihydrotetrabenazine binding in rat striatum: sensitivity to dopamine concentrations. (2010) (33)
- A densitometer for quantitative autoradiography (1983) (33)
- The role of nigrostriatal dopamine in metabotropic glutamate agonist-induced rotation (1998) (33)
- Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with [18F]-FEOBV (2018) (32)
- Quantitative autoradiography of neurotransmitter receptors using tritium-sensitive film. (1981) (32)
- Crossed cerebellar diaschisis: occurrence and resolution demonstrated with PET during carotid temporary balloon occlusion. (1992) (32)
- The Role of Serotonin in Sleep Disordered Breathing Associated with Parkinson Disease: A Correlative [11C]DASB PET Imaging Study (2012) (30)
- Experimental hemiplegia in the monkey: Basal ganglia glucose activity during recovery (1987) (29)
- Impaired contrast sensitivity is associated with more severe cognitive impairment in Parkinson disease. (2017) (28)
- Diminished striatal [123I]iodobenzovesamicol binding in idiopathic cervical dystonia (2003) (28)
- Changes in functional lung regions during the course of radiation therapy and their potential impact on lung dosimetry for non-small cell lung cancer. (2014) (28)
- Quantitative in vivo receptor binding (1986) (28)
- Diabetes, Gray Matter Loss, and Cognition in the Setting of Parkinson Disease. (2016) (27)
- Cerebral benzodiazepine receptor binding in vivo in patients with recurrent hepatic encephalopathy (1997) (27)
- In vitro and in vivo studies of benzisoquinoline ligands for the brain synaptic vesicle monoamine transporter. (1996) (26)
- Educational attainment and motor burden in Parkinson's disease (2015) (26)
- Predictive models for regional hepatic function based on 99mTc-IDA SPECT and local radiation dose for physiologic adaptive radiation therapy. (2013) (26)
- Mutual information for automated multimodal image warping (1996) (25)
- A sequential double-label autoradiographic method that quantifies altered rates of regional glucose metabolism (1985) (25)
- Prevalence of impaired odor identification in Parkinson disease with imaging evidence of nigrostriatal denervation (2016) (24)
- Comparison of Single Time-Point [111-In] Pentetreotide SPECT/CT With Dual Time-Point Imaging of Neuroendocrine Tumors (2011) (24)
- The role of positron emission tomography imaging in movement disorders. (2003) (24)
- Muscarinic Receptor Loss and Preservation of Presynaptic Cholinergic Terminals in Hippocampal Sclerosis (1999) (24)
- ACR-ASNR Practice Parameter for Brain PET/CT Imaging Dementia. (2016) (23)
- Thinning of the Motor–Cingulate–Insular Cortices in Siblings Concordant for Tourette Syndrome (2009) (23)
- Stereotaxic Summation Analysis of Human Cerebral Benzodiazepine Binding Maps (1996) (23)
- Chronic electrical stimulation reverses deafness-related depression of electrically evoked 2-deoxyglucose activity in the guinea pig inferior colliculus (1993) (22)
- Early initiation of hormone therapy in menopausal women is associated with increased hippocampal and posterior cingulate cholinergic activity. (2011) (22)
- Advanced squamous cell carcinoma of the oropharynx: Efficacy of positron emission tomography and computed tomography for determining primary tumor response during induction chemotherapy (2009) (21)
- SNMMI/ABNM Joint Position Statement on Optimizing Training in Nuclear Medicine in the Era of Hybrid Imaging (2012) (21)
- Neurochemical imaging of dementias. (2004) (20)
- Utility of SPECT/CT with Meckel’s scintigraphy (2009) (20)
- Synthesis, 18F-Labeling, and Biological Evaluation of Piperidyl and Pyrrolidyl Benzilates as in Vivo Ligands for Muscarinic Acetylcholine Receptors (2000) (20)
- Assessing Mild Cognitive Impairment with Amyloid and Dopamine Terminal Molecular Imaging (2013) (20)
- 2-Year Natural Decline of Cardiac Sympathetic Innervation in Idiopathic Parkinson Disease Studied with 11C-Hydroxyephedrine PET (2017) (20)
- Co-Registration of MRI and Autoradiography of Rat Brain in Three-Dimensions Following Automatic Reconstruction of 2D Data Set (1995) (19)
- Topography of Cholinergic Changes in Dementia With Lewy Bodies and Key Neural Network Hubs. (2020) (19)
- Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias (2017) (19)
- Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer. (2019) (18)
- Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor – a pharmacokinetic study (2005) (18)
- Development of a tomographic myelin scan (1981) (18)
- Imaging amyloidopathy in Parkinson disease and parkinsonian dementia syndromes (2015) (18)
- [14C]-2-deoxyglucose uptake in monkeys with hypotonic hemiplegia after precentral or postcentral lesions (1980) (18)
- Imaging of monoaminergic and cholinergic vesicular transporters in the brain. (1998) (17)
- ()-α-[11C]Dihydro- tetrabenazine PET imaging in familial paroxysmal dystonic choreoathetosis (1999) (17)
- Procedure guideline for brain death scintigraphy. (2003) (17)
- Scintigraphic portrayal of beta receptors in the heart. (1991) (17)
- Intrastriatal Neurotoxin Injections Reduce in Vitro and in Vivo Binding of Radiolabeled Rotenoids to Mitochondrial Complex I (1997) (17)
- Cerebral amyloid deposition and serotoninergic innervation in Parkinson disease. (2012) (16)
- First-in-Human Studies of [ 18 F] Fluorohydroxyphenethylguanidines (2018) (16)
- Regional cerebral cholinergic nerve terminal integrity and cardinal motor features in Parkinson’s disease (2021) (16)
- Heterogeneity of cholinergic denervation in Parkinson disease (2012) (15)
- Data Extraction from Brain PET Images Using Three-Dimensional Stereotactic Surface Projections (1998) (15)
- Gender differences in cholinergic and dopaminergic deficits in Parkinson disease (2013) (15)
- A Novel Time–Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After 177Lu-DOTATATE (2020) (15)
- First-in-Human Studies of [18F] Fluorohydroxyphenethylguanidines: Positron Emission Tomography Radiotracers for Quantifying Regional Cardiac Sympathetic Nerve Density (2018) (15)
- Effects of Tumor Burden on Reference Tissue Standardized Uptake for PET Imaging: Modification of PERCIST Criteria. (2018) (14)
- Cerebellar metabolic reduction in Alzheimer's disease and data normalization. (1998) (14)
- Non-exercise physical activity attenuates motor symptoms in Parkinson disease independent from nigrostriatal degeneration. (2015) (14)
- Evaluation of [18F]N-methyl-lansoprazole as a tau PET imaging agent in first-in-human studies. (2020) (14)
- Apathy rating scores and β-amyloidopathy in patients with Parkinson disease at risk for cognitive decline (2019) (14)
- Thalamic, brainstem, and cerebellar glucose metabolism in the hemiplegic monkey (1988) (13)
- Imaging of acute pulmonary embolism (2013) (13)
- Advanced age, cardiovascular risk burden, and timed up and go test performance in Parkinson disease. (2014) (13)
- Kinetic Evaluation of Positron-Emitting Muscarinic Receptor Ligands Employing Direct Intracarotid Injection (1996) (13)
- Metabolic response assessment with 18F-FDG PET/CT: inter-method comparison and prognostic significance for patients with non-small cell lung cancer (2015) (12)
- Comparing fludeoxyglucose F18-PET assessment of regional cerebral glucose metabolism and [11C]dihydrotetrabenazine-PET in evaluation of early dementia and mild cognitive impairment. (2010) (12)
- History of falls in Parkinson disease is associated with reduced cholinergic but not nigrostriatal dopaminergic activity (2009) (12)
- Demonstration of prosthetic activation of central auditory pathways using [14C]‐2‐Deoxyglucose (1990) (12)
- A regional metabolic contrast method for the study of brain pathology (1984) (12)
- An updated radiosynthesis of [18F]AV1451 for tau PET imaging (2017) (11)
- Decreased Lung Perfusion After Breast/Chest Wall Irradiation: Quantitative Results From a Prospective Clinical Trial. (2017) (11)
- ABNM Position Statement: Nuclear Medicine Professional Competency and Scope of Practice (2011) (10)
- Equilibrium analysis of [11C]PIB studies (2008) (10)
- Proceedings of the International Cancer Imaging Society (ICIS) 16th Annual Teaching Course (2016) (10)
- Use of 55 PET radiotracers under approval of a Radioactive Drug Research Committee (RDRC) (2020) (9)
- Postmenopausal hormone treatment alters neural pathways but does not improve verbal cognitive function (2018) (9)
- ACR-ACNM Practice Parameter for the Performance of Dopamine Transporter (DaT) Single Photon Emission Computed Tomography (SPECT) Imaging for Movement Disorders. (2017) (9)
- Post‐Mortem evaluation of amyloid‐dopamine terminal positron emission tomography dementia classifications (2015) (9)
- Biodistribution of 99mTc-MAA on SPECT/CT performed for 90Y-radioembolization therapy planning: a pictorial review (2017) (9)
- Human brain receptor distribution. (1986) (8)
- Synthesis and biological evaluation in mice of (2-[11C]methoxy)-6',7'-dihydrorotenol, a second generation rotenoid for marking mitochondrial complex I activity. (1995) (8)
- Technetium-99m-N1-(2-mercapto-2-methylpropyl)-N2-(2-propargylthio-2- methylpropyl)-1,2-benzenediamine (T691): preclinical studies of a potential new tracer of regional cerebral perfusion. (1992) (8)
- The neurochemistry of therapeutics: Levodopa pharmacodynamics in Parkinson's disease (2001) (7)
- Classification of ADNI PET images via regularized 3D functional data analysis (2017) (7)
- Agreement among neuropsychological and behavioral data and PiB findings in diagnosing Frontotemporal Dementia (2017) (7)
- PET imaging of the vesicular acetylcholine transporter (2012) (7)
- Interpretation of metabolic abnormalities in Alzheimer's disease using three-dimensional stereotactic surface projections (3D-SSP) and normal database (1995) (7)
- Cerebral Amyloid Burden and Hoehn and Yahr Stage 3 Scoring in Parkinson Disease. (2017) (7)
- First-in-human studies of 18F-hydroxyphenethylguanidines: PET radiotracers for quantifying cardiac sympathetic nerve density. (2016) (7)
- Amyloid Imaging in Dementia: Contribution or Confusion? (2015) (7)
- (+)-alpha-[11C]Dihydrotetrabenazine PET imaging in familial paroxysmal dystonic choreoathetosis. (1999) (7)
- Effects of plasma glucose levels on regional cerebral 18F-fluorodeoxyglucose uptake: Implications for dementia evaluation with brain PET imaging (2019) (7)
- Utility of delayed whole-body bone scintigraphy after directed three-phase scintigraphy. (2009) (7)
- Reduction of presynaptic monoaminergic vesicles in the striata of parkinsonian patients and in normal human aging. (1995) (6)
- Staging of Differentiated Thyroid Carcinoma Using Diagnostic (2010) (6)
- Evaluation of methoxytetrabenazine as an in vivo tracer of monoamine nerve terminal integrity. (1994) (6)
- Society of Nuclear Medicine Procedure Guideline for Brain Death Scintigraphy version 1 . 0 , approved February 25 , 2003 (2003) (6)
- Color discrimination errors associate with axial motor impairments in Parkinson's Disease (2017) (6)
- Pharmacological characterization of PD102807: An m4 subtype selective muscarinic antagonist (1997) (6)
- Tomography Scans During and After Radiation-Based Therapy in Patients With Non-Small-Cell Lung Cancer (2007) (6)
- Differential effects of scopolamine on in vivo binding of dopamine transporter and vesicular monoamine transporter radioligands in rat brain (2004) (6)
- A Pipeline for Automated Voxel Dosimetry: Application in Patients with Multi-SPECT/CT Imaging After 177Lu-Peptide Receptor Radionuclide Therapy (2022) (5)
- False Positive Diagnosis of Metastatic Esophageal Carcinoma on Positron Emission Tomography: A Case Report of Cholecystitis Simulating a Hepatic Lesion (2010) (5)
- Results of multi-center clinical trials comparing four 18F PET amyloid-imaging agents: Preclinical to clinical correlations (2008) (5)
- FDG-PET/CT during Radiation Therapy to Predict Survival and Guide Individualized Adaptive Dose Escalation in Patients with Non–small-cell Lung Cancer (2009) (5)
- Dopamine depletion increases in vivo [11C]DTBZ binding in awake rat brain (2008) (5)
- Radiosynthesis and comparisons in the biodistribution of carbon‐11 labeled muscarinic antagonists: (+)2α‐tropanyl benzilate and N‐methyl‐4‐piperidyl benzilate (1989) (5)
- Correlation of Continuous EEG Monitoring with [O-15]H2O Positron Emission Tomography Determination of Cerebral Blood Flow during Balloon Test Occlusion of the Internal Carotid Artery (1998) (5)
- Autoradiographic quantification of muscarinic cholinergic synaptic markers in bat, shrew, and rat brain (1994) (5)
- Vertebral body hemangioma visualized on Tc-99m HMPAO-labeled leukocyte SPECT/CT. (2008) (4)
- Neuroimaging in neurotoxicology. (2000) (4)
- 240. Pet measures of monoaminergic synaptic density in bipolar I disorder: Relationship with age of onset (1998) (4)
- Quantifying cardiac sympathetic denervation: first studies of 18F-fluorohydroxyphenethylguanidines in cardiomyopathy patients (2021) (4)
- Quantitative in vivo receptor binding IV: Detection of muscarinic receptor down-regulation by equilibrium and by tracer kinetic methods (1991) (4)
- (-)-6', 7'-[11C]dihydroroten-12α-ol ((-)-[11C]DHROL) for in vivo measurement of mitochondrial complex I (1999) (4)
- Decreased striatal monoaminergic presynaptic terminals in OPCA and MSA demonstrated with [11C]dihydrotetrabenazine and PET. (1995) (4)
- Erratum: Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers (Psychopharmacology (2006) 185 (327-338) DOI: http//dx.doi.org/10.1007/s00213-006-0330-6) (2006) (4)
- Predictive Models for Regional Hepatic Function Based upon 99mTc-IDA SPECT and Local Radiation Dose for Physiological Adaptive RT (2013) (3)
- Investigation of Proposed Activity of Clarithromycin at GABAA Receptors Using [(11)C]Flumazenil PET. (2016) (3)
- Focal hyperemia on RBC blood-flow imaging. A scintigraphic marker of arterioportal venous shunting in hepatic cavernous hemangiomas? (1997) (3)
- [O-15]H2O Positron Emission Tomography Determination of Cerebral Blood Flow Reserve after Intravenous Acetazolamide during Balloon Test Occlusion of the Internal Carotid Artery (1998) (3)
- Molecular Imaging of Extrapyramidal Movement Disorders. (2017) (3)
- Management of Diabetes Mellitus Before 18F-Fluorodeoxyglucose PET/CT: A Nationwide Patient-Centered Assessment of Approaches to Examination Preparation. (2019) (3)
- PET Amyloid Analyses (2016) (3)
- Kinetic evaluation of [C-11]dihydrotetrabenazine (DTBZ) by dynamic PET : a marker for the vesicular monoamine transporter. (1995) (3)
- Surface projection maps of cortical amyloid binding reveal canonical patterns in neurodegenerative dementias (2012) (3)
- 5-tert-Butyl-2-(4'-[18F]fluoropropynylphenyl)-1,3-dithiane oxides: potential new GABA A receptor radioligands. (2008) (3)
- Basal ganglia glucose metabolic and single neural unit activity in experimental hemiplegia. (1984) (3)
- Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? Against. (2002) (3)
- Hepatic Function Model Based Upon HIDA SPECT and Dose for Physiological Adaptive RT. (2013) (2)
- Tritium labeling of potential lipophilic myelin probes (1984) (2)
- Parkinson Dementia: PET Findings (2014) (2)
- Radiotracers and analytical approaches in positron and single-photon emission tomography. (2000) (2)
- Progression of regional cortical cholinergic denervation in Parkinson disease: a longitudinal acetycholinesterase 11C-PMP PET study (2018) (2)
- Imaging VMAT2 in Parkinson disease with [F-18]AV-133 (2008) (2)
- Respiratory motion gated PET with end-expiratory, amplitude based gating (2009) (2)
- Differences in tumor-to-normal organ SUV ratios measured with 68Ga-DOTATATE PET compared with 177Lu-DOTATATE SPECT in patients with neuroendocrine tumors (2022) (2)
- Molecular Imaging of Extrapyramidal Movement Disorders With Dementia: The 4R Tauopathies. (2021) (2)
- Imaging butyrylcholinesterase activity in Alzheimer's disease (2006) (2)
- Gait Speed Is Preserved in Oligosystem Compared to Multisystem Neurodegeneration in Parkinson Disease (P04.165) (2013) (2)
- 158. Decreased vesicular monoamine transporter density in schizophrenic prefrontal cortex (2000) (2)
- Clinical correlation of multivariate spatial covariance analysis of 18F-FEOBV VAChT PET in Parkinson disease (2016) (2)
- Synthesis, (18)F-labeling, and biological evaluation of piperidyl and pyrrolidyl benzilates as in vivo ligands for muscarinic acetylcholine receptors. (2000) (2)
- Apathy but not depression is associated with amyloidopathy in Parkinson disease at risk for dementia (2015) (2)
- Single-Photon Emission Computed Tomography/Computed Tomography as a Problem-Solving Tool in Patients With Suspected Acute Cholecystitis (2013) (2)
- Impaired color perception is associated with more severe nigrostriatal denervation in Parkinson disease (2013) (2)
- Progression of regional cortical cholinergic denervation in Parkinson's disease. (2022) (2)
- Positron Emission Tomography (2019) (1)
- Autoimmune limbic encephalitis detected on FDG brain scan performed for the evaluation of dementia. (2015) (1)
- Updates in Molecular Brain Imaging. (2017) (1)
- The phosphoinositide-linked CNS muscarinic receptor. (1988) (1)
- Using FDG-PET Acquired During the Course of Radiation Therapy to Individualize Adaptive Radiation Dose Escalation in Patients with Non-Small Cell Lung Cancer (2010) (1)
- PET cardiac sympathetic imaging with 11C-hydroxyephedrine in idiopathic Parkinson's disease (2011) (1)
- Odor identification is a more robust measure of forebrain cholinergic activity than odor memory/discrimination tests in Parkinson disease (2013) (1)
- Kinetic evaluation of [C-11] dihydrotetrabenazine : a PET ligand for assessing the vesicular monoamine transporter. (1995) (1)
- Slowing Parkinson’s disease progression: Recent dopamine agonist trials: Reply from the Authors (2004) (1)
- PIB PET 3-site stability study (2007) (1)
- Inter-method Comparison and Optimization of [18F] FDG PET Metabolic Response Assessment in Non-Small Cell Lung Cancer. (2013) (1)
- Cerebellar acetylcholinesterase activity and parkinsonian motor impairment (2008) (1)
- Amyloid PET imaging: a challenge for research in clinical neuroimaging (2015) (1)
- Ratings of activities of daily living are associated with cortical cholinergic but not with the degree of nigrostriatal dopaminergic activity in Parkinson disease (2009) (1)
- Comparing Fludeoxyglucose F 18 – PET Assessment of Regional Cerebral Glucose Metabolism and [ 11 C ] Dihydrotetrabenazine – PET in Evaluation of Early Dementia and Mild Cognitive Impairment (2010) (1)
- Comorbid cortical {beta}-amyloid plaques affect postural instability and gait disorder symptoms in Parkinson disease (2012) (1)
- Methods in Positron Emission Tomography (1999) (1)
- Brain benzodiazepine binding sites in panic disorder (2000) (1)
- Neuroimaging of epilepsy, movement disorders, and degenerative diseases (1993) (1)
- In vitro and in vivo binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is strereospecific. (1995) (1)
- 18F-FDG PET/CT Demonstrates Efficacy and Limitations of Hepatic Arterial Infusion Chemotherapy for Treating Colorectal Liver Metastases (2010) (1)
- The Additional Value of V/Q SPECT over Q SPECT Alone for Pulmonary Function Mapping before, during and after Radiotherapy in Patients with Non–small Cell Lung Cancer (2009) (0)
- Differentiation of Lewy body dementia from Parkinson's disease with [C-11]DTBZ PET (2005) (0)
- Autoradiographic distinction of high and low affinity muscarinic receptors by the m1-selective ligand PD150714 (1995) (0)
- Both cortical cholinergic denervation and cortical {beta}-amyloid plaques contribute to cognitive impairment in Parkinson disease (2012) (0)
- Differential diagnosis of renal masses with PET/CT (2006) (0)
- Routine determination of pulmonary aerosol clearance in V/Q SPECT studies (2008) (0)
- 177Lu-DOTATATE Theranostics (2023) (0)
- The Prevalence of Impaired Olfaction in Parkinson's Disease Is Higher Than Previously Estimated (P07.129) (2012) (0)
- Erratum: Hippocampal inactivation disrupts the acquisition and contextual encoding of fear extinction (Journal of Neuroscience (September 28, 2005) (8978-8987)) (2005) (0)
- Contents of the American Journal of Psychiatry (2005) (0)
- 85. In vivo measurement of presynaptic dopamine innervation in schizophrenia (1998) (0)
- Reverse Translation in Parkinson Disease (2016) (0)
- Single time-point planar and SPECT/CT 111-In pentetreotide scintigraphy: Does it have advantages over dual time-point planar and SPECT imaging? (2008) (0)
- Effect of serum blood glucose on SUV measurements: implications in quantitative brain imaging and implementation of PERCIST criteria (2016) (0)
- Agonists versus levodopa in PD: the thrilla of whitha: Reply from the Authors (2003) (0)
- Utilization of SPECT/CT for the evaluation of suspected acute cholecystitis in problematic cases (2011) (0)
- Pulmonary functional map on V/Q SPECT and TGFβ1 during radiotherapy and post-treatment lung function in patients with non-small cell lung cancer. (2009) (0)
- Heterogeneity of neurodegeneration in Parkinson disease: Variable degree of dopaminergic versus cholinergic denervation (2009) (0)
- Differential cholinergic systems’ changes in progressive supranuclear palsy versus Parkinson’s disease: an exploratory analysis (2022) (0)
- SU‐FF‐J‐34: Can Functional Imaging Be Used to Individualize Adaptive Radiation Therapy for Non‐Small Cell Lung Cancer? (2006) (0)
- Cortical and subcortical cholinergic innervation in normal aging (2010) (0)
- Gender Differences in Dopaminergic and Cholinergic Integrity in Parkinson Disease (P06.080) (2013) (0)
- Physiological and Biochemical Measurements Using Positron Emission Tomography (1999) (0)
- Diagnostic value of 111-In pentetreotide SPECT/CT fusion imaging in the evaluation of neuroendocrine tumors in routine clinical practice (2007) (0)
- 177 Lu-DOTATATE Theranostics Predicting Renal Dosimetry From Pretherapy 68 Ga-DOTATATE PET and Clinical Biomarkers (2023) (0)
- Older age of Parkinson's disease onset associated with increased cognitive impairment, even in patients without dementia (1999) (0)
- Cardiovascular risk factors associate with cholinergic denervation in Parkinson disease (P2.152) (2015) (0)
- In vivo assessment of multiple neurodegenerations and cognitive impairment in Parkinson disease (2014) (0)
- in Normal &ng, AlzheimJs Disease, and Parlunson's Disease (1996) (0)
- Applications of SPECT-CT in lymphoscintigraphy (2006) (0)
- Diabetes Is Associated with Increased Central Neurotoxicity in Parkinson Disease: A Case-Control Study (P06.098) (2013) (0)
- Synthesis of [11C]rotenone and preliminary biodistribution studies in mice and monkey (1994) (0)
- Evaluation of Extrastriatal Specific Binding of [11C]Dihydrotetrabenazine Using Active and Inactive Enantiomers (2001) (0)
- Cholinergic Integrity And Visual Hallucinations In Parkinson Disease (S18.004) (2014) (0)
- Lower Education Status Associates With Axial Motor Burden In Parkinson Disease (P5.265) (2014) (0)
- Selective hyposmia and striatal monoaminergic vesicular binding binding in Parkinson disease (2008) (0)
- Cerebellar vermis vesicular acetylcholine transporter expression and parkinsonian motor impairment (2014) (0)
- Striatal vesicular acetylcholine transporter expression and cognitive function in Parkinson disease (2014) (0)
- PET imaging of metastatic paraganglioma using novel 3-[18F]fluoro-para-hydroxyphenethylguanidine (3-[18F]pHPG) radiotracer (2022) (0)
- Thalamic GABAa Receptor Expression is Inversely Correlated with Axial Motor Impairments in Parkinson Disease (P6.082) (2015) (0)
- The Correlation of Pulmonary FDG PET and Perfusion SPECT Imaging During Radiotherapy for Non-small Cell Lung Cancer (2010) (0)
- Increased frontal lobe white matter lesion burden is associated with increased cortical and raphe nucleus serotonin transporter expression in normal elderly (2012) (0)
- Decreased Vestibular Efficacy Contributes To Balance Impairment in Parkinson Disease (PD4.009) (2012) (0)
- Use of exploratory INDs in evaluation of 18F-labeled PET amyloid plaque imaging agents (2008) (0)
- Dopaminergic and cholinergic correlates of rhythmic foot oscillation control in Parkinson disease (2010) (0)
- Postural sensory efficacy and striatal dopaminergic innervation in normal older adults (2010) (0)
- Limitations of delayed SPECT/CT in the evaluation of parathyroid adenomas (2008) (0)
- In Vivo Mapping of Cholmergic Termina in Normal & ng , Alzheimer ' s Disease , and Parlunson ' s Disease l eri (0)
- REM sleep behavior disorder is associated with cortical cholinergic deficit in Parkinson's disease without dementia (2010) (0)
- WE‐A‐217A‐04: Hepatic Function Estimated from HIDA SPECT for Assessment of Liver Response to Radiation Therapy (2012) (0)
- Invited commentary on "Structural and functional imaging in parkinsonian syndromes". (2014) (0)
- FDG PET Imaging of Childhood Sarcomas 225 (2009) (0)
- The Michigan New Technology Training and Research (MNTR) Translational Program in Nuclear Medicine (Final Report) (2018) (0)
- Decreased Lung Perfusion Following Breast/Chest Wall Irradiation: Preliminary Results of a Prospective Clinical Trial (2014) (0)
- Regional white matter lesions and Pittsburgh compound B retention in cognitively impaired elderly (2013) (0)
- Reply: Cognition and olfaction in Parkinson's disease (2010) (0)
- Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease. (2002) (0)
- A Pilot 11C-Choline PET-CT Imaging Study in Patients With Locally Advanced Esophageal Cancer (2013) (0)
- Molecular Imaging of Neurodegenerative Parkinsonism. (2021) (0)
- Development of a blood test to predict patient [11C]PBR28 binding patterns prior to clinical PET imaging (2012) (0)
- More severe parkinsonism is associated with lower physical activity-related energy expenditure in PD (P7.289) (2015) (0)
- ABNM CertLink: Update and "By the Numbers". (2022) (0)
- 47: Pilot Study on FDG-PET Acquired During and After Fractionated Radiation in Patients With Non-Small Cell Lung Cancer (NSCLC) (2006) (0)
- Clinical Applications of Cerebral Positron Emission Tomography (1999) (0)
- Regional white matter lesions and PIB retention in cognitively impaired elderly (2013) (0)
- O1‐07‐06: Mild Dementia evaluated with [11C]DTBZ and [11C]PiB positron emission tomography (2011) (0)
- Activation of the auditory brainstem of deafened guinea pigs with cochlear stimulation a carbon 14 2 deoxyglucose study (1989) (0)
- Posterior cortical hypometabolism precedes mixed subcortical-cortical metabolic changes in incident dementia in Parkinson disease (2008) (0)
- Invited oral presentations (1997) (0)
- PET neurochemical vs. clinical phenotypes in mild-early dementia (2009) (0)
- Striatal dopaminergic correlates of the Montreal Cognitive Assessment test and the Mini Mental State Exam in Parkinson disease: A [11C]-DTBZ PET study (2012) (0)
- Presence and intensity of tremor reflects subcortical cholinergic but not nigrostriatal dopaminergic innervation changes in Parkinson disease (2010) (0)
- [11C]PiB in patients with amnestic and non-amnestic MCI (2009) (0)
- Technical considerations for SPECT/CT in hepatobiliary imaging (2008) (0)
- Diabetes Is Associated with Bradykinesia and Postural Instability and Gait Difficulty in Parkinson Disease Independent of Nigrostriatal Dopaminergic Denervation: A Case-Control Study (P07.125) (2012) (0)
- Stereospecificity of in vitro and in vivo binding of isomers of alpha-[C-11]dihydrotetrabenazine alpha -[C-11]DTBZ) to vesicular monoamine transporters. (1995) (0)
- Diagnostic yield of whole-body 18F-FDG PET/CT in patients with suspected cardiac sarcoidosis. (2023) (0)
- Mild Dementia evaluated with [11C]DTBZ and [11C]PiB positron emission tomography (2011) (0)
- Imaging Cognitive Dysfunction in Parkinson's Disease (2011) (0)
- Inter-method Variability of [18F]FDG PET Metabolic Response Assessment of Non-small Cell Lung Cancer (NSCLC) (2011) (0)
- Striatal and cortical amyloidopathy and cognitive functions in Parkinson disease at risk of dementia (2015) (0)
- In vivo [C-11]dihydrotetrabenazine binding is unaffected by chronic L-DOPA or deprenyl treatment (1995) (0)
- Bradykinesia, Rigidity, and Postural Instability and Gait Difficulty Occur More Commonly in Men with Parkinson Disease Compared to Women Independent of Nigrostriatal Dopaminergic Denervation (P06.044) (2012) (0)
- Interval Changes Of Forebrain-Cortical Versus Brainstem-Thalamic Cholinergic Integrity In Parkinson Disease Progression (P2.007) (2014) (0)
- Cardiac post-ganglionic sympathetic denervation correlates selectively with REM sleep behavior disorder symptoms in Parkinson disease. (2015) (0)
- Regional covariance of brain cholinergic terminal changes in Parkinson disease: an 18F-FEOBV PET study (2016) (0)
- Development of a Tomographc Myelin Scan (1981) (0)
- In Vivo Imaging of Benzodiazepine Receptors with Positron Emission Tomography (2020) (0)
- Pattern of cardiac s ympathetic Denervation in idiopathic Parkinson Disease s tudied with (2012) (0)
- Reply: Alzheimer Disease: Approaches to Early Diagnosis and High-Accuracy Imaging (2015) (0)
- Cholinergic and dopaminergic PET imaging of gait in Parkinson disease (2010) (0)
- Variability in foot-tapping as a new biomarker of nigrostriatal dopaminergic denervation in Parkinson's disease (2009) (0)
- Cognitive correlates of posterior cingulate hypometabolism in Parkinson disease (2008) (0)
- Twelfth annual symposia on etiology, pathogenesis, and treatment of parkinson's disease and etiology, pathogenesis, and treatment of Huntington's disease (1998) (0)
- Reply (0)
- Shape analysis method can be used for limited non-invasive estimation of striatal and cerebellar [11C]-PMP k3 hydrolysis rates (2011) (0)
- H 20 Positron Emission Tomography Determination of Cerebral Blood Flow during Balloon Test Occlusion of the Internal Carotid Artery (2013) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Kirk A. Frey?
Kirk A. Frey is affiliated with the following schools: